All Stories

  1. Oral relugolix for the treatment of advanced prostate cancer

    Article • The Oncologist, January 2026, Oxford University Press (OUP)

    Dr Michael Lock

  2. Practical Aspects of Delivering Radiation for Polymetastatic Disease

    Article • International Journal of Radiation Oncology*Biology*Physics, January 2026, Elsevier

    Dr Michael Lock

  3. Ultrahypofractionated Versus Conventionally Fractionated Whole-pelvis Radiotherapy in Prostate Cancer: A Randomized Clinical Trial

    Article • European Urology Oncology, January 2026, Elsevier

    Dr Michael Lock

  4. The Dilemma of Choice: Options for Nonoperable Hepatocellular Carcinoma Management

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2025, Elsevier

    Dr Michael Lock

  5. 1477P Overall survival among 4913 patients with hepatocellular carcinoma treated with external beam radiation therapy: Individual patient data outcomes from a multinational cohort

    Article • Annals of Oncology, September 2025, Elsevier

    Dr Michael Lock

  6. Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial

    Article • The Lancet Oncology, September 2025, Elsevier

    Dr Michael Lock

  7. Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High Risk Adenocarcinoma of the Prostate (PCS VI)

    Article • International Journal of Radiation Oncology*Biology*Physics, September 2025, Elsevier

    Dr Michael Lock

  8. Comparison of CellSearch versus Parsortix circulating tumor cell enumeration and molecular characterization: A pilot study in metastatic prostate cancer patients

    Article • Next Research, June 2025, Elsevier

    Dr Michael Lock

  9. 1634 Is hypofractionated whole-pelvis RT (WPRT) as well tolerated as conventional WPRT in prostate cancer? Analysis of the Hope trial primary endpoint

    Article • Radiotherapy and Oncology, May 2025, Elsevier

    Dr Michael Lock

  10. Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis

    Article • The Lancet Oncology, March 2025, Elsevier

    Dr Michael Lock

  11. Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis

    Article • Supportive Care in Cancer, February 2025, Springer Science + Business Media

    Dr Michael Lock

  12. Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: A randomized phase II trial (GROUQ-PCS 9).

    Article • Journal of Clinical Oncology, February 2025, American Society of Clinical Oncology (ASCO)

    Dr Michael Lock

  13. Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma

    Article • JAMA Oncology, February 2025, American Medical Association (AMA)

    Dr Michael Lock

  14. Enteral and parenteral nutrition in patients with cancer: complication rates compared—updated systematic review and meta-analysis

    Article • BMJ Supportive & Palliative Care, January 2025, BMJ

    Dr Michael Lock

  15. Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial

    Article • International Journal of Radiation Oncology*Biology*Physics, January 2025, Elsevier

    Dr Michael Lock

  16. Left atrial myxoma metastasizing to the brain: a case report and review of literature

    Article • Radiation Oncology Journal, December 2024, Korean Society for Therapeutic Radiology and Oncology (KAMJE)

    Dr Michael Lock

  17. Ablative Radiation Therapy to Restrain Everything Safely Treatable (ARREST): A Phase 1 Study of Stereotactic Ablative Radiation Therapy for Polymetastatic Disease

    Article • International Journal of Radiation Oncology*Biology*Physics, December 2024, Elsevier

    Dr Michael Lock

  18. Helical Tomotherapy Versus 3-Dimensional Conformal Radiation Therapy in High-Risk Prostate Cancer: A Phase 3 Randomized Controlled Trial

    Article • International Journal of Radiation Oncology*Biology*Physics, December 2024, Elsevier

    Dr Michael Lock

  19. Acute Cardiac Inflammation 1-Year after Left-Sided Breast Cancer Radiotherapy Assessed with Hybrid PET/MRI

    Article • International Journal of Radiation Oncology*Biology*Physics, October 2024, Elsevier

    Dr Michael Lock

  20. Prognostic Index for Liver Radiation (PILiR)

    Article • Current Oncology, September 2024, MDPI AG

    Dr Michael Lock

  21. A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol

    Article • BMC Palliative Care, September 2024, Springer Science + Business Media

    Dr Michael Lock

  22. 423P Marginalization and factors associated with early mortality among patients diagnosed with de novo metastatic breast cancer in Ontario, Canada

    Article • Annals of Oncology, September 2024, Elsevier

    Dr Michael Lock

  23. Diagnostic CT-Enabled Planning (DART): Results of a Randomized Trial in Palliative Radiation Therapy

    Article • International Journal of Radiation Oncology*Biology*Physics, September 2024, Elsevier

    Dr Michael Lock

  24. Prognostic Index for Liver Radiation (PILiR)

    Article • August 2024, MDPI AG

    Dr Michael Lock

  25. Barrier films or dressings for the prevention of acute radiation dermatitis in breast cancer: a systematic review and network meta-analysis

    Article • Breast Cancer Research and Treatment, August 2024, Springer Science + Business Media

    Dr Michael Lock

  26. Malignant Phyllodes Tumors of the Breast With Rhabdomyosarcomatous Differentiation: A Case Report and Literature Review

    Article • Cureus, July 2024, Springer Science + Business Media

    Dr Michael Lock

  27. Is Ultrahypofractionated Whole Pelvis Radiation Therapy (WPRT) as Well Tolerated as Conventionally Fractionated WPRT in Patients With Prostate Cancer? Early Results From the HOPE Trial

    Article • International Journal of Radiation Oncology*Biology*Physics, July 2024, Elsevier

    Dr Michael Lock

  28. A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients with Up to 10 Oligometastases and a Synchronous Primary Tumor (SABR-SYNC): Study Protocol

    Article • June 2024, Springer Science + Business Media

    Dr Michael Lock

  29. The Current Role of Radiation in the Management of Cholangiocarcinoma—A Narrative Review

    Article • Cancers, May 2024, MDPI AG

    Dr Michael Lock

  30. 315: ARREST – A phase I study of SABR for poly-metastatic disease.

    Article • Radiotherapy and Oncology, May 2024, Elsevier

    Dr Michael Lock

  31. Dose-response of localized renal cell carcinoma after stereotactic body radiation therapy: A meta-analysis

    Article • Radiotherapy and Oncology, May 2024, Elsevier

    Dr Michael Lock

  32. Immunotherapy and Radiation Therapy Sequencing in Breast Cancer: A Systematic Review

    Article • International Journal of Radiation Oncology*Biology*Physics, April 2024, Elsevier

    Dr Michael Lock

  33. Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidance for the prevention of breast cancer-related arm lymphoedema (BCRAL): international Delphi consensus-based recommendations

    Article • EClinicalMedicine, February 2024, Elsevier

    Dr Michael Lock

  34. Stereotactic Body Radiation Therapy (SBRT) Versus Transarterial Chemoembolization (TACE) for Treatment Of Hepatocellular Carcinoma: a Meta-Analysis of Propensity Matched Studies

    Article • University of Toronto Medical Journal, January 2024, University of Toronto Libraries - UOTL

    Dr Michael Lock

  35. Re: Deng and Heybati

    Article • JNCI Journal of the National Cancer Institute, November 2023, Oxford University Press (OUP)

    Dr Michael Lock

  36. Diagnostic CT-Enabled Radiation Therapy (DART): Results of a Randomized Trial for Palliative Radiation Therapy

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2023, Elsevier

    Dr Michael Lock

  37. Palliative radiotherapy for hepatic tumors: a narrative review of indications and recommendations

    Article • Annals of Palliative Medicine, November 2023, AME Publishing Company

    Dr Michael Lock

  38. Treatment modalities to manage hepatocellular carcinoma patients with portal vein thrombosis: a systematic review and meta-analysis

    Article • Annals of Palliative Medicine, November 2023, AME Publishing Company

    Dr Michael Lock

  39. Complication Avoidance of Reconstruction Implant Radiation Therapy (CARIT): A Retrospective Case-Cohort Analysis

    Article • International Journal of Radiation Oncology*Biology*Physics, October 2023, Elsevier

    Dr Michael Lock

  40. Long-Term Outcomes of NRG/RTOG 0126, a Randomized Trial of High Dose (79.2 Gy) vs. Standard Dose (70.2 Gy) Radiation Therapy (RT) for Men with Localized Prostate Cancer

    Article • International Journal of Radiation Oncology*Biology*Physics, October 2023, Elsevier

    Dr Michael Lock

  41. Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High Risk Adenocarcinoma of the Prostate (PCS VI): Acute Toxicity Results

    Article • International Journal of Radiation Oncology*Biology*Physics, October 2023, Elsevier

    Dr Michael Lock

  42. Radiotherapy for Liver Cancer: An International Multi-Centre Pooled Analysis of 925 Cases

    Article • International Journal of Radiation Oncology*Biology*Physics, October 2023, Elsevier

    Dr Michael Lock

  43. Treatment Modalities to Manage Hepatocellular Carcinoma Patients with Portal Vein Thrombus: A Systematic Review and Meta-Analysis

    Article • International Journal of Radiation Oncology*Biology*Physics, October 2023, Elsevier

    Dr Michael Lock

  44. 112 Is Hypofractionated Whole-Pelvis Radiotherapy (WPRT) as Well Tolerated as Conventionally Fractionated WPRT in Prostate Cancer Patients? An Early Analysis of the Hope-Trial

    Article • Radiotherapy and Oncology, September 2023, Elsevier

    Dr Michael Lock

  45. 57 Ablative Radiation Therapy to Restrain Everything Safely Treatable (ARREST) - a Phase 1 Study of SABR for Poly-Metastatic Disease

    Article • Radiotherapy and Oncology, September 2023, Elsevier

    Dr Michael Lock

  46. Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)—a systematic review and individual patient data meta-analysis

    Article • Supportive Care in Cancer, August 2023, Springer Science + Business Media

    Dr Michael Lock

  47. What’s to come in PSMA therapies and diagnostics: A summary of clinical trials involving PSMA radioligand-based therapeutic and/or diagnostic approaches with active recruitment

    Article • Expert Review of Anticancer Therapy, June 2023, Taylor & Francis

    Dr Michael Lock

  48. Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial

    Article • Journal of Clinical Oncology, June 2023, American Society of Clinical Oncology (ASCO)

    Dr Michael Lock

  49. PET/MRI Assessment of Acute Cardiac Inflammation 1 Month After Left-Sided Breast Cancer Radiation Therapy

    Article • Journal of Nuclear Medicine Technology, May 2023, Society of Nuclear Medicine

    Dr Michael Lock

  50. A Rare Case of Recurrent Cutaneous Non-Hodgkin’s Lymphoma in the Extremity: Long-Term Follow-Up and Review of the Literature Written With the Assistance of ChatGPT

    Article • Cureus, April 2023, Springer Science + Business Media

    Dr Michael Lock

  51. Are Radiation Target Volumes for Postmastectomy Radiation Therapy Too Large? Initial Report of the Complication Avoidance of Reconstruction Implant Radiation Therapy (CARIT) Study

    Article • Current Oncology, February 2023, MDPI AG

    Dr Michael Lock

  52. NRG/RTOG 1112: Randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC).

    Article • Journal of Clinical Oncology, February 2023, American Society of Clinical Oncology (ASCO)

    Dr Michael Lock

  53. Use of artificial intelligence for cancer clinical trial enrollment: a systematic review and meta-analysis

    Article • JNCI Journal of the National Cancer Institute, January 2023, Oxford University Press (OUP)

    Dr Michael Lock

  54. NRG/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937)

    Article • International Journal of Radiation Oncology*Biology*Physics, December 2022, Elsevier

    Dr Michael Lock

  55. Assessing Acute Cardiac Inflammation after Left-Sided Breast Cancer Radiotherapy with Hybrid PET/MRI (RICT-BREAST)

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2022, Elsevier

    Dr Michael Lock

  56. Development of a Support Vector Machine-Based Tool for Survival Prediction after Stereotactic Body Radiotherapy for Liver Metastases Using Multi-Institutional Data

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2022, Elsevier

    Dr Michael Lock

  57. Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2022, Elsevier

    Dr Michael Lock

  58. Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysis

    Article • BMJ Supportive & Palliative Care, September 2022, BMJ

    Dr Michael Lock

  59. Does stereotactic body radiation improve outcomes compared to conventional radiation for liver cancer patients?

    Article • Clinical and Translational Radiation Oncology, July 2022, Elsevier

    Dr Michael Lock

  60. Dosimetric Planning Comparison for Left-Sided Breast Cancer Radiotherapy: The Clinical Feasibility of Four-Dimensional-Computed Tomography-Based Treatment Planning Optimization

    Article • Cureus, May 2022, Springer Science + Business Media

    Dr Michael Lock

  61. Assessing Acute Cardiac Inflammation One Month after Left-sided Breast Cancer Radiotherapy with Hybrid PET/MRI

    Article • May 2022, Springer Science + Business Media

    Dr Michael Lock

  62. OC-0104 Stereotactic radiation for treatment of oligometastases (SABR-COMET) – Extended long-term outcomes

    Article • Radiotherapy and Oncology, May 2022, Elsevier

    Dr Michael Lock

  63. Comparing treatment modalities for hepatocellular carcinoma: the value of network meta-analyses

    Article • Acta Oncologica, January 2022, Acta Dermato-Venereologica

    Dr Michael Lock

  64. Radiotherapy and radiosensitization in breast cancer: Molecular targets and clinical applications

    Article • Critical Reviews in Oncology/Hematology, January 2022, Elsevier

    Dr Michael Lock

  65. Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126

    Article • International Journal of Radiation Oncology*Biology*Physics, January 2022, Elsevier

    Dr Michael Lock

  66. Radiofrequency ablation vs radiation therapy vs transarterial chemoembolization vs yttrium 90 for local treatment of liver cancer – a systematic review and network meta-analysis of survival data

    Article • Acta Oncologica, November 2021, Acta Dermato-Venereologica

    Dr Michael Lock

  67. Dose Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Suppression for Intermediate Risk Prostate Cancer: Outcomes From the NRG Oncology/RTOG 0815 Randomized Trial

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2021, Elsevier

    Dr Michael Lock

  68. Re-Evaluating the Toxicity of Radiotherapy in Patients With Collagen Vascular Disease: A Meta-Analysis of Propensity Score Studies

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2021, Elsevier

    Dr Michael Lock

  69. Prophylaxis and treatment of cancer-related dyspnea with pharmacologic agents: A systematic review and network meta-analysis

    Article • Palliative & Supportive Care, October 2021, Cambridge University Press

    Dr Michael Lock

  70. Weight changes of younger and older early breast cancer patients—a meta regression

    Article • Annals of Palliative Medicine, October 2021, AME Publishing Company

    Dr Michael Lock

  71. Cancer-related fatigue—pharmacological interventions: systematic review and network meta-analysis

    Article • BMJ Supportive & Palliative Care, September 2021, BMJ

    Dr Michael Lock

  72. Esophageal Cancer Radiotherapy Dose Escalation Meta Regression Commentary: “High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma With Modern Radiotherapy Techniques: A Meta-Analysis”

    Article • Frontiers in Oncology, July 2021, Frontiers

    Dr Michael Lock

  73. Abstract 2701: Molecular profiling to assess the immune response to neoadjuvant SABR in early breast cancer

    Article • Cancer Research, July 2021, American Association for Cancer Research (AACR)

    Dr Michael Lock

  74. Redefining postmastectomy radiation contouring in the era of immediate breast reconstruction: An accurate assessment of local recurrence risk

    Article • Clinical and Translational Radiation Oncology, July 2021, Elsevier

    Dr Michael Lock

  75. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019

    Article • Current Oncology, May 2021, MDPI AG

    Dr Michael Lock

  76. Weight Change of Younger and Older Early Breast Cancer Patients – A Meta Regression

    Article • May 2021, Springer Science + Business Media

    Dr Michael Lock

  77. Intrafraction motion monitoring to determine PTV margins in early stage breast cancer patients receiving neoadjuvant partial breast SABR

    Article • Radiotherapy and Oncology, May 2021, Elsevier

    Dr Michael Lock

  78. Secondary and cumulative meta-analysis of olanzapine for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: do we still need to study its effectiveness?

    Article • Annals of Palliative Medicine, March 2021, AME Publishing Company

    Dr Michael Lock

  79. Cost Minimization Analysis of Hypofractionated Radiotherapy

    Article • Current Oncology, January 2021, MDPI AG

    Dr Michael Lock

  80. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature

    Article • Supportive Care in Cancer, January 2021, Springer Science + Business Media

    Dr Michael Lock

  81. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients

    Article • Supportive Care in Cancer, January 2021, Springer Science + Business Media

    Dr Michael Lock

  82. The addition of radiofrequency ablation for patients receiving sorafenib: new evidence for a new standard?

    Article • Annals of Translational Medicine, January 2021, AME Publishing Company

    Dr Michael Lock

  83. Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging

    Article • Advances in Radiation Oncology, January 2021, Elsevier

    Dr Michael Lock

  84. Hydroxychloroquine for the treatment of COVID-19: the importance of scrutiny of positive trials

    Article • Annals of Palliative Medicine, November 2020, AME Publishing Company

    Dr Michael Lock

  85. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Randomized Trial

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2020, Elsevier

    Dr Michael Lock

  86. Is hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? The HOPE trial

    Article • BMC Cancer, October 2020, Springer Science + Business Media

    Dr Michael Lock

  87. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial

    Article • Journal of Clinical Oncology, September 2020, American Society of Clinical Oncology (ASCO)

    Dr Michael Lock

  88. 8: Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-Comet Randomized Trial

    Article • Radiotherapy and Oncology, September 2020, Elsevier

    Dr Michael Lock

  89. The Effect of Registration on Voxel-Wise Tofts Model Parameters and Uncertainties from DCE-MRI of Early-Stage Breast Cancer Patients Using 3DSlicer

    Article • Journal of Digital Imaging, August 2020, Springer Science + Business Media

    Dr Michael Lock

  90. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients

    Article • Breast Cancer Research and Treatment, July 2020, Springer Science + Business Media

    Dr Michael Lock

  91. Corrigendum to “Single vs multiple fraction palliative radiation therapy for bone metastases: Cumulative meta-analysis” [Radiother Oncol 141 (2019) 56–61]

    Article • Radiotherapy and Oncology, July 2020, Elsevier

    Dr Michael Lock

  92. Patterns of Failure Observed in the 2-Step Institution Credentialing Process for NRG Oncology/Radiation Therapy Oncology Group 1005 (NCT01349322) and Lessons Learned

    Article • Practical Radiation Oncology, July 2020, Elsevier

    Dr Michael Lock

  93. Consensus Statement on Tumour Bed Localization for Radiation after Oncoplastic Breast Surgery

    Article • Current Oncology, June 2020, MDPI AG

    Dr Michael Lock

  94. How robust are the results of one of the first positive trials exploring hydroxychloroquine for treatment of COVID-19?

    Article • May 2020, openRxiv

    Dr Michael Lock

  95. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial

    Article • March 2020, openRxiv

    Dr Michael Lock

  96. A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy

    Article • International Journal of Radiation Oncology*Biology*Physics, March 2020, Elsevier

    Dr Michael Lock

  97. DCE-MRI assessment of response to neoadjuvant SABR in early stage breast cancer: Comparisons of single versus three fraction schemes and two different imaging time delays post-SABR

    Article • Clinical and Translational Radiation Oncology, March 2020, Elsevier

    Dr Michael Lock

  98. Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis

    Article • Supportive Care in Cancer, January 2020, Springer Science + Business Media

    Dr Michael Lock

  99. Inter-rater reliability in performance status assessment among healthcare professionals: an updated systematic review and meta-analysis

    Article • Supportive Care in Cancer, January 2020, Springer Science + Business Media

    Dr Michael Lock

  100. Correction to: Enteral and parenteral nutrition in cancer patients, a comparison of complication rates: an updated systematic review and (cumulative) meta-analysis

    Article • Supportive Care in Cancer, December 2019, Springer Science + Business Media

    Dr Michael Lock

  101. Enteral and parenteral nutrition in cancer patients, a comparison of complication rates: an updated systematic review and (cumulative) meta-analysis

    Article • Supportive Care in Cancer, December 2019, Springer Science + Business Media

    Dr Michael Lock

  102. Inter-rater reliability in performance status assessment between clinicians and patients: a systematic review and meta-analysis

    Article • BMJ Supportive & Palliative Care, December 2019, BMJ

    Dr Michael Lock

  103. Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial

    Article • International Journal of Radiation Oncology*Biology*Physics, December 2019, Elsevier

    Dr Michael Lock

  104. Recurrence and Mortality after Breast-Conserving Surgery without Radiation

    Article • Current Oncology, December 2019, MDPI AG

    Dr Michael Lock

  105. Single vs multiple fraction palliative radiation therapy for bone metastases: Cumulative meta-analysis

    Article • Radiotherapy and Oncology, December 2019, Elsevier

    Dr Michael Lock

  106. Symptoms Predictive of Overall Quality of Life Using the Edmonton Symptom Assessment Scale in Breast Cancer Patients Receiving Radiotherapy

    Article • Clinical Breast Cancer, December 2019, Elsevier

    Dr Michael Lock

  107. A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis

    Article • Advances in Radiation Oncology, October 2019, Elsevier

    Dr Michael Lock

  108. 132 Prognostic Index for Localized Liver Radiation - Metastatic (PILLiR-M): Development and Analysis of a Clinical Prognostic Tool to Improve Patient Selection for Liver Directed Radiotherapy for Liver Metastases

    Article • Radiotherapy and Oncology, October 2019, Elsevier

    Dr Michael Lock

  109. 156 Validation and Inter-Rater Reliability of Two Metrics Used as Predictors of Heart Dose in Patients Treated with Adjuvant Radiotherapy to the Left Breast

    Article • Radiotherapy and Oncology, October 2019, Elsevier

    Dr Michael Lock

  110. 34 Dosimetric Comparison and Toxicity Analysis of Stereotactic Radiotherapy for High-Risk Prostate Cancer

    Article • Radiotherapy and Oncology, October 2019, Elsevier

    Dr Michael Lock

  111. 91 Quality of Life Outcomes After Stereotactic Ablative Radiotherapy (SABR) Versus Standard of Care Palliative Treatments: A Secondary Analysis of the SABR-COMET Randomized Trial

    Article • Radiotherapy and Oncology, October 2019, Elsevier

    Dr Michael Lock

  112. Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis

    Article • Critical Reviews in Oncology/Hematology, October 2019, Elsevier

    Dr Michael Lock

  113. Symptom clusters in patients with breast cancer receiving radiation therapy

    Article • European Journal of Oncology Nursing, October 2019, Elsevier

    Dr Michael Lock

  114. Dosimetric Comparison and Toxicity Analysis of Stereotactic Radiotherapy for High-Risk Prostate Cancer

    Article • International Journal of Radiation Oncology*Biology*Physics, September 2019, Elsevier

    Dr Michael Lock

  115. Prognostic Index for Localized Liver Radiation – Hepatocellular Carcinoma (PILLiR-HCC): Development and Analysis of a Clinical Prognostic Tool to Improve Patient Selection for Liver Directed Radiotherapy in Patients with Hepatocellular Carcinoma

    Article • International Journal of Radiation Oncology*Biology*Physics, September 2019, Elsevier

    Dr Michael Lock

  116. Prognostic Index for Localized Liver Radiation – Metastatic (PILLiR-M): Development and Analysis of a Clinical Prognostic Tool to Improve Patient Selection for Liver Directed Radiotherapy for Liver Metastases

    Article • International Journal of Radiation Oncology*Biology*Physics, September 2019, Elsevier

    Dr Michael Lock

  117. Quality of Life Outcomes after Stereotactic Ablative Radiotherapy (SABR) vs. Standard of Care Palliative Treatments: A Secondary Analysis of the SABR-COMET Randomized Trial

    Article • International Journal of Radiation Oncology*Biology*Physics, September 2019, Elsevier

    Dr Michael Lock

  118. Validation and Inter-Rater Reliability of Two Metrics Used As Predictors of Heart Dose in Patients Treated with Adjuvant Radiotherapy to the Left Breast

    Article • International Journal of Radiation Oncology*Biology*Physics, September 2019, Elsevier

    Dr Michael Lock

  119. Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial

    Article • BMC Cancer, August 2019, Springer Science + Business Media

    Dr Michael Lock

  120. Phase III Randomized Pair Comparison of a Barrier Film vs. Standard Skin Care in Preventing Radiation Dermatitis in Post-lumpectomy Patients with Breast Cancer Receiving Adjuvant Radiation Therapy

    Article • Cureus, June 2019, Springer Science + Business Media

    Dr Michael Lock

  121. Stereotactic Image-Guided Neoadjuvant Ablative Single-Dose Radiation, then Lumpectomy, for Early Breast Cancer: The Signal Prospective Single-Arm Trial of Single-Dose Radiation Therapy

    Article • Current Oncology, June 2019, MDPI AG

    Dr Michael Lock

  122. Prostate Cancer, Gender Identity, and Testosterone Replacement Therapy in Klinefelter Syndrome: A Case Report and Literature Review

    Article • Cureus, May 2019, Springer Science + Business Media

    Dr Michael Lock

  123. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

    Article • The Lancet, May 2019, Elsevier

    Dr Michael Lock

  124. Reducing the dose of gadolinium-based contrast agents for DCE-MRI guided SBRT: The effects on inter and intra observer variability for preoperative target volume delineation in early stage breast cancer patients

    Article • Radiotherapy and Oncology, February 2019, Elsevier

    Dr Michael Lock

  125. Prognostic Significance of Tumor Location for Liver Cancer Radiotherapy

    Article • Cureus, December 2018, Springer Science + Business Media

    Dr Michael Lock

  126. Appropriate Treatment Receipt after Breast-Conserving Surgery

    Article • Current Oncology, December 2018, MDPI AG

    Dr Michael Lock

  127. Radiobiologically Guided Radiation Therapy in Large Primary and Metastatic Hepatic Lesions

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2018, Elsevier

    Dr Michael Lock

  128. Stereotactic ablative radiotherapy for oligometastatic cancers: Efficacy and toxicity results from the randomized SABR-COMET Trial

    Article • Annals of Oncology, November 2018, Elsevier

    Dr Michael Lock

  129. Results of a Prospective Cohort Trial: Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then Lumpectomy (SIGNAL) for Early-Stage Breast Cancer

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2018, Elsevier

    Dr Michael Lock

  130. Stereotactic Ablative Radiation Therapy for the Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): Results of a Randomized Trial

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2018, Elsevier

    Dr Michael Lock

  131. Phase II Trial of Pure Hypofractionated Radiotherapy in the Treatment of Localized Carcinoma of the Prostate

    Article • Cureus, October 2018, Springer Science + Business Media

    Dr Michael Lock

  132. Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer

    Article • Breast Cancer Research and Treatment, August 2018, Springer Science + Business Media

    Dr Michael Lock

  133. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer

    Article • JAMA Oncology, June 2018, American Medical Association (AMA)

    Dr Michael Lock

  134. Patient-perceived barriers to radiation therapy for breast cancer

    Article • Canadian Journal of Surgery, April 2018, Canadian Medical Association (CMA)

    Dr Michael Lock

  135. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies

    Article • Technology in Cancer Research & Treatment, January 2018, SAGE Publications

    Dr Michael Lock

  136. The Utility of Penile Bulb Contouring to Localise the Prostate Apex as Compared to Urethrography

    Article • Journal of Medical Imaging and Radiation Sciences, November 2017, Elsevier

    Dr Michael Lock

  137. Lessons Learned From the Two-Step QA Process in NRG Oncology/RTOG 1005, A Phase 3 Trial for Early-Stage Breast Cancer

    Article • International Journal of Radiation Oncology*Biology*Physics, October 2017, Elsevier

    Dr Michael Lock

  138. Advances in external beam stereotactic body radiotherapy: principle concerns in implementing a liver radiation program

    Article • Chinese Clinical Oncology, September 2017, AME Publishing Company

    Dr Michael Lock

  139. Reducing Patient Waiting Times for Radiation Therapy and Improving the Treatment Planning Process: a Discrete-event Simulation Model (Radiation Treatment Planning)

    Article • Clinical Oncology, June 2017, Elsevier

    Dr. Mehmet A. Begen, Dr Michael Lock

  140. EP-1365: Pure Hypofractionated Radiotherapy for the Treatment of Low- to Intermediate-Risk Prostate Cancer

    Article • Radiotherapy and Oncology, May 2017, Elsevier

    Dr Michael Lock

  141. Potential benefit of rotational radiation therapy

    Article • Future Oncology, April 2017, Future Medicine

    Dr Slav Yartsev, Dr Michael Lock

  142. A multivariable model to predict survival for patients with hepatic carcinoma or liver metastasis receiving radiotherapy

    Article • Future Oncology, January 2017, Future Medicine

    Dr Michael Lock, Dr Slav Yartsev

  143. Strategies to tackle the challenges of external beam radiotherapy for liver tumors

    Article • World Journal of Hepatology, January 2017, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Michael Lock

  144. Stereotactic Body Radiotherapy

    Article • January 2017, Springer Science + Business Media

    Dr Michael Lock

  145. Computed tomography imaging assessment of postexternal beam radiation changes of the liver

    Article • Future Oncology, December 2016, Future Medicine

    Dr Michael Lock

  146. Postediting prostate magnetic resonance imaging segmentation consistency and operator time using manual and computer-assisted segmentation: multiobserver study

    Article • Journal of Medical Imaging, November 2016, SPIE

    Dr Michael Lock

  147. Predicting which patients actually receive radiation following breast conserving therapy in Canadian populations

    Article • Canadian Journal of Surgery, October 2016, Canadian Medical Association (CMA)

    Dr Michael Lock

  148. 92: Identification of Patients that will not Benefit from Hepatic Radiation

    Article • Radiotherapy and Oncology, September 2016, Elsevier

    Dr Michael Lock

  149. Sci‐Fri AM: MRI and Diagnostic Imaging ‐ 03: The influence of sampling percentage in deformable registration on kinetic model analysis results in DCE‐MRI of the breast

    Article • Medical Physics, August 2016, Wiley

    Dr Michael Lock

  150. Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions

    Article • Expert Review of Anticancer Therapy, April 2016, Informa Healthcare

    Dr Michael Lock

  151. A Single Institution Consensus on the Use of Sequential or Concurrent Hormonal Therapy for Breast Cancer Patients Receiving Radiation Therapy

    Article • Cureus, April 2016, Cureus, Inc.

    Dr Michael Lock

  152. Evaluation of Health Economics in Radiation Oncology: A Systematic Review

    Article • International Journal of Radiation Oncology*Biology*Physics, April 2016, Elsevier

    Dr Michael Lock

  153. A phase II trial to evaluate single-dose stereotactic body radiation therapy (SBRT) prior to surgery for early-stage breast carcinoma: SIGNAL (stereotactic image-guided neoadjuvant ablative radiation then lumpectomy) trial

    Article • Journal of Radiation Oncology, November 2015, Springer Science + Business Media

    Dr Michael Lock

  154. A Systematic Review of Health Economic Evaluations in Radiation Oncology

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2015, Elsevier

    Dr Michael Lock

  155. Bowel and Bladder Function of Men on a Phase 3 Randomized Study of High Versus Standard Dose of 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2015, Elsevier

    Dr Michael Lock

  156. Concurrent or Sequential Hormonal and Radiation Therapy in Breast Cancer: A Literature Review.

    Article • Cureus, October 2015, Cureus, Inc.

    Dr Michael Lock

  157. Abscopal Effects: Case Report and Emerging Opportunities

    Article • Cureus, October 2015, Cureus, Inc.

    Dr Michael Lock

  158. How has SBRT progressed in different countries and what this can teach us in the future

    Article • Future Oncology, October 2015, Future Medicine

    Dr Michael Lock, Dr Eric L Chang

  159. The significance of circulating tumor cells in prostate cancer patients undergoing adjuvant or salvage radiation therapy

    Article • Prostate Cancer and Prostatic Diseases, August 2015, Nature

    Dr Michael Lock

  160. A case-control, mono-center, open-label, pilot study to evaluate the feasibility of therapeutic touch in preventing radiation dermatitis in women with breast cancer receiving adjuvant radiation therapy

    Article • Complementary Therapies in Medicine, August 2015, Elsevier

    Dr Michael Lock

  161. A Phase 1/2 Trial of Brief Androgen Suppression and Stereotactic Radiation Therapy (FASTR) for High-Risk Prostate Cancer

    Article • International Journal of Radiation Oncology*Biology*Physics, July 2015, Elsevier

    Dr Michael Lock

  162. Dosimetric Comparison of Volumetric Modulated Arc Therapy, Tomotherapy and Intensity Modulated Radiation Therapy for Radiation Dose Escalation of Hepatic Malignancies

    Article • Journal of Medical Imaging and Radiation Sciences, March 2015, Elsevier

    Dr Slav Yartsev, Dr Michael Lock

  163. A randomized trial of 79.2Gy versus 70.2Gy radiation therapy (RT) for localized prostate cancer.

    Article • Journal of Clinical Oncology, March 2015, American Society of Clinical Oncology (ASCO)

    Dr Michael Lock

  164. Initial Results of a Phase 3 Randomized Study of High Dose 3DCRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer (RTOG 0126)

    Article • International Journal of Radiation Oncology*Biology*Physics, December 2014, Elsevier

    Dr Michael Lock

  165. Stereotactic body radiotherapy: an effective local treatment modality for hepatocellular carcinoma

    Article • Future Oncology, November 2014, Future Medicine

    Dr Michael Lock

  166. In Regard to Parikh et al

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2014, Elsevier

    Dr Michael Lock

  167. Spatially varying accuracy and reproducibility of prostate segmentation in magnetic resonance images using manual and semiautomated methods

    Article • Medical Physics, November 2014, Wiley

    Dr Michael Lock

  168. Variation in Clinical Target Volumes for Post-prostatectomy Patients and Effect on Normal Tissue Complication Probability

    Article • Cureus, October 2014, Springer Science + Business Media

    Dr Michael Lock

  169. Increased Plasma IL-17F Levels in Rheumatoid Arthritis Patients Are Responsive to Methotrexate, Anti-TNF, and T Cell Costimulatory Modulation

    Article • Inflammation, September 2014, Springer Science + Business Media

    Mukundan Attur, Dr Michael Lock

  170. Dosimetric Comparison of Volumetric Modulated Arc Therapy, Tomotherapy, and Intensity Modulated Radiation Therapy for Radiation Dose Escalation of Hepatic Malignancies

    Article • International Journal of Radiation Oncology*Biology*Physics, September 2014, Elsevier

    Dr Michael Lock

  171. Identification of Patients With Liver Cancer That Will Not Benefit From Radiation

    Article • International Journal of Radiation Oncology*Biology*Physics, September 2014, Elsevier

    Dr Michael Lock

  172. Feasibility of Preoperative Volumetric-Modulated Arc Therapy for Early Stage Breast Cancer

    Article • Journal of Medical Imaging and Radiation Sciences, June 2014, Elsevier

    Dr Michael Lock

  173. Phase III Randomized Pair Comparison of a Barrier Film vs. Standard Skin Care in Preventing Radiation Dermatitis in Women with Breast Cancer Receiving Adjuvant Radiation Therapy

    Article • Journal of Medical Imaging and Radiation Sciences, June 2014, Elsevier

    Dr Michael Lock

  174. Assessment of contrast enhanced respiration managed cone-beam CT for image guided radiotherapy of intrahepatic tumors

    Article • Medical Physics, April 2014, Wiley

    Dr Michael Lock

  175. Dynamic contrast enhanced CT aiding gross tumor volume delineation of liver tumors: An interobserver variability study

    Article • Radiotherapy and Oncology, April 2014, Elsevier

    Dr Michael Lock

  176. Effects of registration error on parametric response map analysis: a simulation study using liver CT-perfusion images

    Article • Journal of Physics Conference Series, March 2014, Institute of Physics Publishing

    Dr Michael Lock

  177. Graded-threshold parametric response maps: towards a strategy for adaptive dose painting

    Article • Journal of Physics Conference Series, March 2014, Institute of Physics Publishing

    Dr Michael Lock

  178. PO-0705: Phase I/II study of image-guided and radiobiologically guided radiotherapy for hepatic lesions

    Article • Radiotherapy and Oncology, January 2014, Elsevier

    Dr Michael Lock

  179. PO-0976: Feasibility of preoperative volumetric-modulated arc therapy for early stage breast cancer

    Article • Radiotherapy and Oncology, January 2014, Elsevier

    Dr Michael Lock

  180. Phase 1 Study of Image-Guided and Radiobiologically-Guided Stereotactic Body Radiation Therapy for Hepatic Lesions

    Article • International Journal of Radiation Oncology*Biology*Physics, October 2013, Elsevier

    Dr Michael Lock

  181. Prostate Cancer Brachytherapy: Does Real-Time Dynamic Ultrasound Planning With Continuous Feedback Produce Dosimetry Predictive of the Subsequent CT/MRI Dose Distribution?

    Article • International Journal of Radiation Oncology*Biology*Physics, October 2013, Elsevier

    Dr Michael Lock

  182. Cost-minimization analysis: should partial breast irradiation be utilized over whole breast irradiation assuming equivalent clinical outcomes?

    Article • Cureus, August 2013, Springer Science + Business Media

    Dr Michael Lock

  183. Determination and comparison of radiotherapy dose responses for hepatocellular carcinoma and metastatic colorectal liver tumours

    Article • British Journal of Radiology, July 2013, Oxford University Press (OUP)

    Dr Michael Lock

  184. Prediction and Reduction of Motion Artifacts in Free-Breathing Dynamic Contrast Enhanced CT Perfusion Imaging of Primary and Metastatic Intrahepatic Tumors

    Article • Academic Radiology, April 2013, Elsevier

    Dr Michael Lock

  185. Automated IMRT planning with regional optimization using planning scripts

    Article • Journal of Applied Clinical Medical Physics, January 2013, Wiley

    Dr Michael Lock

  186. Improving the Efficiency of Radiation Therapy Delivery by Resource Optimization

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2012, Elsevier

    Dr Michael Lock, Dr. Mehmet A. Begen

  187. Gleason Pattern 5 is Associated With an Increased Risk for Metastasis Following Androgen Deprivation Therapy (ADT) and Radiation: An Analysis of RTOG 9202 and 9902

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2012, Elsevier

    Dr Michael Lock

  188. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial

    Article • BMC Cancer, July 2012, Springer Science + Business Media

    Dr Michael Lock

  189. Fitness to Drive in Patients with Brain Tumours: The Influence of Mandatory Reporting Legislation on Radiation Oncologists in Canada

    Article • Current Oncology, June 2012, MDPI AG

    Dr Michael Lock

  190. An international survey on liver metastases radiotherapy

    Article • Acta Oncologica, May 2012, Acta Dermato-Venereologica

    Dr Michael Lock

  191. Radiotherapy for Liver Metastases: A Review of Evidence

    Article • International Journal of Radiation Oncology*Biology*Physics, March 2012, Elsevier

    Dr Michael Lock

  192. The Impact of Post-Mastectomy Radiation Therapy on Male Breast Cancer Patients—A Case Series

    Article • International Journal of Radiation Oncology*Biology*Physics, February 2012, Elsevier

    Dr Michael Lock

  193. Circulating tumour cells in prostate cancer patients receiving salvage radiotherapy

    Article • Revista de Oncología, February 2012, Springer Science + Business Media

    Dr Michael Lock

  194. Development of an Automated Atlas-based Segmentation Technology Assessment Methodology

    Article • International Journal of Radiation Oncology*Biology*Physics, October 2011, Elsevier

    Dr Michael Lock

  195. Fitness to Drive in Patients with Brain Tumors: The Influence of Mandatory Reporting Legislation in Canada

    Article • International Journal of Radiation Oncology*Biology*Physics, October 2011, Elsevier

    Dr Michael Lock

  196. Case-cohort study to determine the value of therapeutic touch in preventing radiation dermatitis.

    Article • Journal of Clinical Oncology, September 2011, American Society of Clinical Oncology (ASCO)

    Dr Michael Lock

  197. A Phase II Trial of Arc-Based Hypofractionated Intensity-Modulated Radiotherapy in Localized Prostate Cancer

    Article • International Journal of Radiation Oncology*Biology*Physics, August 2011, Elsevier

    Dr Michael Lock

  198. Phase I Trial of Simultaneous In-Field Boost With Helical Tomotherapy for Patients With One to Three Brain Metastases

    Article • International Journal of Radiation Oncology*Biology*Physics, July 2011, Elsevier

    Dr Michael Lock

  199. SU-E-U-07: Comparison of 3D Ultrasound Prostate Localization with Electronic Portal Imaging of Fiducial Markers

    Article • Medical Physics, June 2011, Wiley

    Dr Michael Lock

  200. TH-E-110-08: Free Breathing Hepatic CT Perfusion with Automatic a Posteriori Motion Correction

    Article • Medical Physics, June 2011, Wiley

    Dr Michael Lock

  201. Brachytherapy with permanent gold grain seeds for squamous cell carcinoma of the lip

    Article • Radiotherapy and Oncology, March 2011, Elsevier

    Dr Michael Lock

  202. Technology assessment of automated atlas based segmentation in prostate bed contouring

    Article • Radiation Oncology, January 2011, Springer Science + Business Media

    Dr Michael Lock

  203. Radiation recall dermatitis due to gemcitabine does not suggest the need to discontinue chemotherapy

    Article • Oncology Letters, October 2010, Spandidos Publications

    Dr Michael Lock

  204. Effective and cost-effective clinical trial recruitment strategies for postmenopausal women in a community-based, primary care setting

    Article • Contemporary Clinical Trials, September 2010, Elsevier

    Dr Michael Lock

  205. SU-GG-I-101: 3D Segmentation and Rigid Registration for Minimizing Breathing Motion Effects in Liver CT Perfusion

    Article • Medical Physics, June 2010, Wiley

    Dr Michael Lock

  206. A phase II trial of arc-based hypofractionated IMRT in localized prostate cancer.

    Article • Journal of Clinical Oncology, May 2010, American Society of Clinical Oncology (ASCO)

    Dr Michael Lock

  207. 188 THE CLINICAL IMPACT OF VARIATION IN CLINICAL TARGET VOLUMES FOR POST-PROSTATECTOMY PATIENTS

    Article • Radiotherapy and Oncology, September 2009, Elsevier

    Dr Michael Lock

  208. Systematic review of dose–volume parameters in the prediction of esophagitis in thoracic radiotherapy

    Article • Radiotherapy and Oncology, June 2009, Elsevier

    Dr Michael Lock

  209. TH‐C‐304A‐09: Semi‐Automatic Respiratory Motion Correction for Liver CT Perfusion

    Article • Medical Physics, June 2009, Wiley

    Dr Michael Lock

  210. Salvage radiotherapy following radical prostatectomy

    Article • International Journal of Urology, December 2008, Wiley

    Dr Michael Lock

  211. Mathematical modeling of liver metastases tumour growth and control with radiotherapy

    Article • Physics in Medicine and Biology, December 2008, Institute of Physics Publishing

    Dr Michael Lock

  212. Inter- and Intra-observer Agreement in Clinical Target Volumes for Post-prostatectomy Patients

    Article • International Journal of Radiation Oncology*Biology*Physics, September 2008, Elsevier

    Dr Michael Lock

  213. Flow cytometric assessment of monocyte activation markers and circulating endothelial cells in patients with localized or metastatic breast cancer

    Article • Cytometry Part B Clinical Cytometry, August 2008, Wiley

    Dr Michael Lock

  214. Poster - Thurs Eve-04: Mathematical modeling of liver metastases tumour growth and control with radiotherapy

    Article • Medical Physics, July 2008, Wiley

    Dr Michael Lock

  215. Brachytherapy with permanent gold grain seeds for squamous cell carcinoma of the lip

    Article • Brachytherapy, April 2008, Elsevier

    Dr Michael Lock

  216. Gabapentin for the treatment of menopausal hot flashes

    Article • Menopause, March 2008, Wolters Kluwer Health

    Dr Michael Lock

  217. Comparing two strategies of dynamic intensity modulated radiation therapy (dIMRT) with 3-dimensional conformal radiation therapy (3DCRT) in the hypofractionated treatment of high-risk prostate cancer

    Article • Radiation Oncology, January 2008, Springer Science + Business Media

    Dr Michael Lock, Dr Slav Yartsev

  218. Hepatic Lesion Radiotherapy: A New Option?

    Article • Canadian Journal of Gastroenterology, January 2008, Hindawi Publishing Corporation

    Dr Michael Lock

  219. Correlation of Clinically Significant Radiation Esophagitis With Dose-Volume Histogram Parameters in Lung Cancer

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2007, Elsevier

    Dr Michael Lock

  220. Systematic review of baseline low-dose CT lung cancer screening

    Article • Lung Cancer, November 2007, Elsevier

    Dr Michael Lock

  221. Development and psychometric properties of the Prostate Cancer Radiation Toxicity Questionnaire

    Article • Journal of Clinical Oncology, June 2007, American Society of Clinical Oncology (ASCO)

    Dr Michael Lock

  222. A Prospective Evaluation of Helical Tomotherapy

    Article • International Journal of Radiation Oncology*Biology*Physics, June 2007, Elsevier

    Dr Michael Lock

  223. Psychometric properties of a prostate cancer radiation late toxicity questionnaire

    Article • Health and Quality of Life Outcomes, May 2007, Springer Science + Business Media

    Dr Michael Lock

  224. Oxybutynin for refractory hot flashes in cancer patients

    Article • Menopause, May 2007, Wolters Kluwer Health

    Dr Michael Lock

  225. Minimal decrease in hot flashes desired by postmenopausal women in family practice

    Article • Menopause, March 2007, Wolters Kluwer Health

    Dr Michael Lock

  226. 2840

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2006, Elsevier

    Dr Michael Lock

  227. 2322

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2006, Elsevier

    Dr Michael Lock

  228. 2327

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2006, Elsevier

    Dr Michael Lock

  229. Clinical Implementation of Adaptive Helical Tomotherapy: A Unique Approach to Image-Guided Intensity Modulated Radiotherapy

    Article • Technology in Cancer Research & Treatment, October 2006, SAGE Publications

    Dr Michael Lock

  230. A comparison of prostate IMRT and helical tomotherapy class solutions

    Article • Radiotherapy and Oncology, September 2006, Elsevier

    Dr Michael Lock, Dr Slav Yartsev

  231. 23 An NTCP formalism accounting for complications from radiation treatment and tumour invasion

    Article • Radiotherapy and Oncology, September 2006, Elsevier

    Dr Michael Lock

  232. 107 Effectiveness of ditropan for the treatment of hot flashes in cancer patients: A single centre retrospective review

    Article • Radiotherapy and Oncology, September 2006, Elsevier

    Dr Michael Lock

  233. 113 Outcome analysis of prostate cancer patients presenting with PSA >50 Ng/MI

    Article • Radiotherapy and Oncology, September 2006, Elsevier

    Dr Michael Lock

  234. 156 Gynaecologic HDR Interstitial Brachytherapy: The Role of Radiation Oncology Nursing in Multi-disciplinary Care

    Article • Radiotherapy and Oncology, September 2006, Elsevier

    Dr Michael Lock

  235. 190 A comparison of optical infrared camera and spirometry guided respiratory gating for liver radiotherapy

    Article • Radiotherapy and Oncology, September 2006, Elsevier

    Dr Michael Lock

  236. 237 Regional recurrence in women with high risk stages I to IIb breast cancer after lumpectomy, systemic therapy, and breast only radiotherapy

    Article • Radiotherapy and Oncology, September 2006, Elsevier

    Dr Michael Lock

  237. 33 Hypofractionated prostate arc radiotherapy using ultrasound localization

    Article • Radiotherapy and Oncology, September 2006, Elsevier

    Dr Michael Lock

  238. 82 Comparing two strategies of dynamic intensity modulated radiation therapy using helical tomotherapy versus 3D conformal radiation therapy in the hypofractionated treatment of the pelvis in high risk prostate cancer

    Article • Radiotherapy and Oncology, September 2006, Elsevier

    Dr Michael Lock

  239. Prostate contouring uncertainty in megavoltage computed tomography images acquired with a helical tomotherapy unit during image-guided radiation therapy

    Article • International Journal of Radiation Oncology*Biology*Physics, June 2006, Elsevier

    Dr Michael Lock

  240. TH‐C‐ValB‐01: Prostate Contouring Uncertainty in Mega‐Voltage Computed Tomography (MVCT) Images Acquired with a Helical Tomotherapy Unit During Image‐Guided Radiation Therapy (IGRT)

    Article • Medical Physics, June 2006, Wiley

    Dr Michael Lock

  241. Assessing the Prognostic Significance of Transrectal Ultrasound Extracapsular Extension in Prostate Cancer

    Article • Clinical Oncology, March 2006, Elsevier

    Dr Michael Lock

  242. 22 Development find Psychometric Properties of the Prostate Cancer Radiation Toxicity Questionnaire

    Article • Radiotherapy and Oncology, September 2005, Elsevier

    Dr Michael Lock

  243. 104 An interactive three-dimensional atlas of nodal topography for radiotherapy treatment planning education

    Article • Radiotherapy and Oncology, September 2005, Elsevier

    Dr Michael Lock

  244. 12 Evaluation of 3D-ultrasound Image Guided Radiotherapy in Prostate Cancer Compared to Implanted Fiducial Markers

    Article • Radiotherapy and Oncology, September 2005, Elsevier

    Dr Michael Lock

  245. 27 Accuracy of Prostate Cancer Staging at a Tertiary Care Cancer Centre

    Article • Radiotherapy and Oncology, September 2005, Elsevier

    Dr Michael Lock

  246. 55 Limits and limitations of MRI and CT lymphatic target volume delineation: Analysis of the visible human high resolution anatomic data sets

    Article • Radiotherapy and Oncology, September 2005, Elsevier

    Dr Michael Lock

  247. 87 Application of helical tomotherapy to palliative and radical genitourinary malignancies

    Article • Radiotherapy and Oncology, September 2005, Elsevier

    Dr Michael Lock

  248. Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer

    Article • International Journal of Radiation Oncology*Biology*Physics, May 2005, Elsevier

    Dr Michael Lock

  249. Intensity-modulated arc therapy for treatment of high-risk endometrial malignancies

    Article • International Journal of Radiation Oncology*Biology*Physics, March 2005, Elsevier

    Dr Michael Lock

  250. Follicular Dendritic Cell Sarcoma: Case Report and Review of Current Management Principles

    Article • The Journal of Otolaryngology, January 2005, Decker, Inc.

    Dr Michael Lock

  251. Prognostic factors in brain metastases: can we determine patients who do not benefit from whole-brain radiotherapy?

    Article • Clinical Oncology, August 2004, Elsevier

    Dr Michael Lock

  252. Prediction of radiation pneumonitis by dose–volume histogram parameters in lung cancer—a systematic review

    Article • Radiotherapy and Oncology, May 2004, Elsevier

    Dr Michael Lock

  253. Megavoltage Computed Tomography Imaging: A Potential Tool to Guide and Improve the Delivery of Thoracic Radiation Therapy

    Article • Clinical Lung Cancer, March 2004, Elsevier

    Dr Michael Lock

  254. Breast Edema during Radiotherapy Can Result in Underdosing

    Article • The Cancer Journal, November 2003, Wolters Kluwer Health

    Dr Michael Lock

  255. Impact of urethrography on geometric uncertainty in prostate cancer radiotherapy

    Article • International Journal of Radiation Oncology*Biology*Physics, October 2003, Elsevier

    Dr Michael Lock

  256. Megavoltage CT imaging for adaptive helical tomotherapy of lung cancer

    Article • International Journal of Radiation Oncology*Biology*Physics, October 2003, Elsevier

    Dr Michael Lock

  257. 150 Small cell carcinoma of the head and neck: experience of a single comprehensive cancer centre

    Article • European Journal of Cancer Supplements, September 2003, Elsevier

    Dr Michael Lock

  258. 183 Intensity modulated arc therapy and carboplatin/paclitaxel chemotherapy for treatment of high-risk endometrial malignancies

    Article • European Journal of Cancer Supplements, September 2003, Elsevier

    Dr Michael Lock

  259. 891 Impact of urethrography in high-precision prostate cancer radiotherapy

    Article • European Journal of Cancer Supplements, September 2003, Elsevier

    Dr Michael Lock

  260. Consolidative abdomino-pelvic radiotherapy following surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer

    Article • International Journal of Radiation Oncology*Biology*Physics, October 2002, Elsevier

    Dr Michael Lock

  261. Prognostic factors in brain metastases: can we determine predictors of early death

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2001, Elsevier

    Dr Michael Lock

  262. Hodgkin's disease — stage ia and iia: omission of pelvic irradiation in clinically and laparotomy staged patients

    Article • International Journal of Radiation Oncology*Biology*Physics, September 1981, Elsevier

    Dr Michael Lock